CLL14: feasibility of fixed-duration frontline therapy in CLL

Fixed-duration treatment strategies for frontline and relapsed CLLПодробнее

The future of fixed-duration therapy in CLLПодробнее

Factors to consider when selecting between continuous and fixed-duration therapy in CLLПодробнее

CLL14 trial analysisПодробнее

Comparing continuous and fixed duration therapy in CLLПодробнее

Challenges of selecting frontline therapy in CLLПодробнее

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLLПодробнее

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLLПодробнее

CLL14: Venetoclax plus obinutuzumab in untreated CLLПодробнее

Frontline ibrutinib + venetoclax in CLL: Results from a fixed duration cohort of the CAPTIVATE studyПодробнее

Frontline, fixed-duration venetoclax/obinutuzumab: PFS and MRD data from CLL14Подробнее

Unanswered questions in frontline CLL treatmentПодробнее

Obinutuzumab + Venetoclax for Frontline CLLПодробнее

Fixed-duration vs continuous therapy in CLLПодробнее

Dr. Cohen on Fixed-Duration Therapy in CLLПодробнее

The optimum approach to frontline treatment of CLL in 2021Подробнее

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses CIT in frontline CLLПодробнее

CLL14: Venetoclax plus obinutuzumab for CLLПодробнее

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLLПодробнее